WuXi Biologics Cayman : 41th Annual J.P. Morgan Healthcare Conference Presentation (in

Global Premier CRDMO:

Enabling Global Partners and

Delivering Sustainable High Growth

Chris Chen PhD

41st Annual J.P. Morgan Healthcare Conference

January 11, 2023

Stock Code: 2269.HK

Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward- looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended

to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should

not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

2

CONTENTS

01	Business Update	02	Summary of Company's
Performance Post IPO

03	ESG as an Important Component	04	Summary
of Business Strategy

3

Business Update 01

R in CRDMO: Exciting Validation

WuXi Biologics and GSK Enter into License

Agreement on Multiple Novel

Bi- & Multi-specific T Cell Engagers

• WuXi Biologics will provide an exclusive license to GSK for 1 preclinical bispecific T cell engaging (TCE) antibody and 3 additional bi- /multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms
• WuXi Biologics will receive an upfront
  payment of US$40 million, up to
  ~US$1.4 billion at key milestones and tiered royalties on net sales

• Goal of WuXi Biologics is to develop exceptional technology platforms to serve global clients
• Low-toxicityCD3, WuXiBody® and SDArBodYTM bi-/multi-specific technologies: potential best in class for cancer therapeutics
• This deal fully validates our business model
• A clear demonstration of CRDMO: 4 potential subsequent development and commercial mfg programs

5